Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na ïve chronic hepatitis B patients in Japan

ConclusionsLong-term entecavir treatment of nucleos(t)ide analogue-na ïve CHB patients was associated with an excellent viral response and a low rate of entecavir-resistant mutations at 10 years. Baseline HBsAg levels and genotype were predictors of HBsAg seroclearance during entecavir treatment.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research